Phase 2 N=156 Seroquel for Frequent, Heavy Drinkers
Alcoholism
Primary: TimeLine Follow Back (TLFB) to Measure Percent Heavy Drinking Days During the Medication/Placebo Phase — 20; 24 percent days of heavy drinking — p=.388
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
Chronic Hepatitis C
Primary: Sustained Virological Response, (HCV RNA Neg.) in Serum 24 Weeks Off Therapy. — 3 participants
Phase 2 N=20 Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Disease Control Rate — 25 percentage of participants
Phase 2 N=69 Combined Treatment for Alcohol-Dependent Individuals With PTSD
Stress Disorders, Post-Traumatic · Alcohol Abuse · Substance-Related Disorders
Primary: Heavy Drinking Days/Week — 3.13; 2.89; 1.05; 0.48 Days/Week — p=0.34
Phase 2 N=33 Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Time-to-Treatment Failure (Intent-To-Treat Analysis) — 4.9; 2.7; 2.2; 3.7 months
Phase 2 N=44 A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0…
Phase 2 N=123 Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
Lung Cancer
Primary: Progression-Free Survival — 4.1; 3.9 months
Phase 2 N=155 Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
Graft Versus Host Disease · Hematologic Malignancies
Primary: Number of Participants With Severe (Grade 3 and 4) Acute Graft Versus Host Disease (GVHD) — 12; 12; 60; 62 Participants — p=0.929
Phase 2 N=12 Functional Electrical Stimulation (FES) Driven Stepping in Individuals With Spinal Cord Injury
Spinal Cord Injury
Primary: Change in Motor and Sensory Scores of the ASIA Impairment Scale (AIS) — 1.0; 2.7; 2.4; -1.2 scores on AIS Scale
Phase 2 N=47 Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 95.7; 83.3 percentage of participants
Phase 2 N=29 Naltrexone and Hypoglycemia in Type 1 Diabetes
Type 1 Diabetes · Hypoglycemia Unawareness
Primary: Cerebral Blood Flow — 1.7; 1.3 percentage of signal intensity change
Phase 2 N=28 Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
HIV Infection
Primary: Change From Baseline in HIV DNA in PBMCs at Week 56 — 0.00; 0.04 log^10 copies per 10^6 PBMCs
Phase 2 N=44 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
Lymphoma
Primary: Complete Response Rate After Remission Induction — 66 percentage of participants
Phase 2 N=84 Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
HIV · Cancer
Primary: Rate of Seroconversion After 1 Dose of Vaccine — 31; 0; 50; 22 percentage of participants
Phase 2 N=129 A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis
Osteopenia
Primary: Percentage Change From Baseline to Week 54 of Lumbar Spine Bone Mineral Density of Active Compared to Placebo. — 1.03; -0.12 percent change — p=0.0265